IDEXX Laboratories (IDXX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
14 May, 2026Opening remarks and agenda
Meeting called to order by the Independent Non-Executive Board Chair, with introductions of key executives and board members, including the announcement of CEO transition effective immediately after the meeting.
Virtual format used for the 10th consecutive year to facilitate broad shareholder participation, with agenda and rules of conduct accessible online.
Retiring board member M. Anne Szostak recognized for 14 years of service and contributions to governance and succession planning.
Board and executive committee updates
CEO transition announced: Jay Mazelsky stepping down as President and CEO to become Executive Chair; Mike Erickson, CEO-elect, to assume CEO role and join the Board.
Board composition updated with recognition of retiring member and introduction of PricewaterhouseCoopers representatives.
Shareholder proposals
Six proposals presented: five management proposals and one shareholder proposal.
Shareholder proposal (Proposal 6) sought to allow shareholders owning 10% of shares to call a special meeting; management countered with Proposal 5, setting a 25% threshold.
Shareholder proponent argued Proposal 5's requirements were overly restrictive and urged support for Proposal 6.
Latest events from IDEXX Laboratories
- Q1 2026 revenue up 14%, EPS up 17%, and guidance raised on strong diagnostics growth.IDXX
Q1 20266 May 2026 - Double-digit revenue and EPS growth in 2025, with strong 2026 outlook and innovation momentum.IDXX
Q4 202513 Apr 2026 - 2025 saw robust growth, innovation, and governance changes, with key shareholder votes ahead.IDXX
Proxy filing27 Mar 2026 - Key votes include director elections, auditor ratification, and board declassification.IDXX
Proxy filing27 Mar 2026 - 2025 saw robust growth, innovation, and governance changes, with key shareholder votes ahead.IDXX
Proxy Filing13 Mar 2026 - Innovation and global expansion drive double-digit growth and new diagnostic adoption.IDXX
47th Annual Raymond James Institutional Investor Conference2 Mar 2026 - Strong innovation-led growth and margin expansion expected to continue into 2026.IDXX
BofA Securities Animal Health Summit26 Feb 2026 - Q2 revenue up 6%–7%, but EPS down 9% on litigation; gross margin rises to 61.7%.IDXX
Q2 20242 Feb 2026 - Double-digit growth driven by innovation, new diagnostics, and global expansion.IDXX
Investor Day 20242 Feb 2026